Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States

References

• National Cancer Institute Surveillance Epidemiology and End Results Program. Cancer stat facts: melanoma of the skin; [cited 2018 Oct 30]. Available from: https://seer.cancer.gov/statfacts/html/melan.html
   Google Scholar
• Rastrelli M, Tropea S, Rossi CR, et al. Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. In Vivo. 2014;28:1005–1011.
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Survival Rates for Melanoma; 2016 [cited 2018 October 31]. Available from: https://www.cancer.org/cancer/melanoma-skin-cancer/detection-diagnosis-staging/survival-rates-for-melanoma-skin-cancer-by-stage.html
   Google Scholar
• Stone M. Surgical management of metastatic melanoma: UpToDate; 2016 [cited 2018 October 30]. Available from: https://www.uptodate.com/contents/surgical-management-of-metastatic-melanoma
   Google Scholar
• Mayo Clinic. Melanoma diagnosis and treatment 2016 [cited 2018 October 31]. Available from: https://www.mayoclinic.org/diseases-conditions/melanoma/diagnosis-treatment/drc-20374888
   Google Scholar
• Kudchadkar RR, Michielin O, van Akkooi A. Practice-changing developments in stage III melanoma: surgery, adjuvant targeted therapy, and immunotherapy. Am Soc Clin Oncol Educ Book. 2018;23:759–762.
   Google Scholar
• Garbe C, Peris K, Hauschild A, et al. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2016. Eur J Cancer. 2016;63:201–217.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Melanoma. NCCN clinical practice guidelines in oncology. Version 1.2019. [cited 2019 Feb 15]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf
   Google Scholar
• Sondak VK, Wolfe JA. Adjuvant therapy for melanoma. Curr Opin Oncol. 1997;9:189–204.
   PubMedGoogle Scholar
• Herndon TM, Demko SG, Jiang X, et al. US Food and Drug Administration Approval: peginterferon-alfa-2b for the adjuvant treatment of patients with melanoma. Oncologist. 2012;17:1323–1328.
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Ibrahim JG, Sondak VK, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol.. 2000;18:2444–2458.
   PubMed Web of Science ®Google Scholar
• Atkins MB, Kunkel L, Sznol M, et al. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am. 2000;6:S11–S14.
   PubMed Web of Science ®Google Scholar
• Schachter J, Ribas A, Long GV, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017;390:1853–1862.
   PubMed Web of Science ®Google Scholar
• Hodi FS, Chiarion-Sileni V, Gonzalez R, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19:1480–1492.
   PubMed Web of Science ®Google Scholar
• Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372:30–39.
   PubMed Web of Science ®Google Scholar
• Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378:1789–1801.
   PubMed Web of Science ®Google Scholar
• Eggermont AMM, Chiarion-Sileni V, Grob J-J, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16:522–530.
   PubMed Web of Science ®Google Scholar
• Eggermont AMM, Chiarion-Sileni V, Grob J-J, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med.. 2016;375:1845–1855.
   PubMed Web of Science ®Google Scholar
• Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377:1824–1835.
   PubMed Web of Science ®Google Scholar
• Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med.. 2017;377:1813–1823.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Highlights of Prescribing Information; 2011 [cited 2018 October 30]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125377s087lbl.pdf
   Google Scholar
• Abdul-Karim RM, Cowey CL. Challenging the standard of care in advanced melanoma: focus on pembrolizumab. Cancer Manag Res. 2017;9:433–442.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Yervoy: EPAR – Product Information. 2011 [cited 2018 July 26]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/yervoy.
   Google Scholar
• Merck & Co. Keytruda (pembrolizumab): prescribing information; 2018. [cited 2018 July 26]. Available from: https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf
   Google Scholar
• Committee for Medicinal Products for Human Use. Summary of opinion (post authorisation): Keytruda; 2018 [cited 2018 July 26]. Available from: https://www.ema.europa.eu/documents/smop/chmp-post-authorisation-summary-positive-opinion-keytruda-ii-42ii-43_en.pdf
   Google Scholar
• European Society for Medical Oncology. EMA recommends pembrolizumab for the adjuvant treatment of melanoma; 2018 [cited 2018 October 25]. Available from: https://www.esmo.org/Oncology-News/EMA-Recommends-Pembrolizumab-for-the-Adjuvant-Treatment-of-Melanoma
   Google Scholar
• Wang J, Chmielowski B, Pellissier J, et al. Cost-effectiveness of pembrolizumab versus ipilimumab in ipilimumab-naive patients with advanced melanoma in the United States. JMCP. 2017;23:184–194.
   PubMed Web of Science ®Google Scholar
• Miguel LS, Lopes FV, Pinheiro B, et al. Cost effectiveness of pembrolizumab for advanced melanoma treatment in Portugal. Value Health. 2017;20:1065–1073.
   PubMedGoogle Scholar
• Marriott E, Praet C, Aguiar-Ibanez R, et al. Cost-effectiveness of pembrolizumab for unresectable metastatic melanoma after progression with ipilimumab in England. Value Health. 2015;18:A453.
   PubMed Web of Science ®Google Scholar
• Hillner BE, Kirkwood JM, Atkins MB, et al. Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684. J Clin Oncol. 1997;15:2351–2358.
   PubMed Web of Science ®Google Scholar
• Cormier JN, Xing Y, Ding M, et al. Cost effectiveness of adjuvant interferon in node-positive melanoma. J Clin Oncol. 2007;25:2442–2448.
   PubMed Web of Science ®Google Scholar
• Crott R, Ali F, Burdette‐Radoux S. Cost-utility of adjuvant high-dose interferon alpha therapy in stage III cutaneous melanoma in Quebec . Value Health. 2004;7:423–432.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Larriba JL, Serrano S, Alvarez-Mon M, et al. Cost-effectiveness analysis of interferon as adjuvant therapy in high-risk melanoma patients in Spain. Eur J Cancer. 2000;36.18:2344–2352.
   Web of Science ®Google Scholar
• Messori A, Becagli P, Trippoli S, et al. A retrospective cost-effectiveness analysis of interferon as adjuvant therapy in high-risk resected cutaneous melanoma. Eur J Cancer. 1997;33:1373–1379.
   PubMed Web of Science ®Google Scholar
• Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316:1093–1103.
   PubMed Web of Science ®Google Scholar
• Bureau of Labor Statistics. Consumer price index: Medical care commodities in U.S. city average, all urban consumers, not seasonally adjusted. 2019. [cited 2019 Jan 5]. Available from: https://beta.bls.gov/dataViewer/view/timeseries/CUUR0000SAM1
   Google Scholar
• Williams C, Lewsey JD, Briggs AH, et al. Cost-effectiveness analysis in R using a multi-state modeling survival analysis framework: a tutorial. Med Decis Making. 2017;37:340–352.
   PubMed Web of Science ®Google Scholar
• Williams C, Lewsey JD, Mackay DF, et al. Estimation of survival probabilities for use in cost-effectiveness analyses: a comparison of a multi-state modeling survival analysis approach with partitioned survival and Markov Decision-Analytic modeling. Med Decis Making. 2017;37:427–439.
   PubMed Web of Science ®Google Scholar
• Arias E, Heron M, Xu J. United States Life Tables, 2014. Natl Vital Stat Rep. 2017;66:1–64.
   Google Scholar
• Flatiron Health. Flatiron database. 2018. [cited 2018 Dec 15]. Available from: http://www.flatiron.com/real-world-evidence
   Google Scholar
• National Institute for Health and Care Excellence. DSU Technical Support Document 19: Partitioned survival analysis for decision modelling in health care: a critical review. 2017. [cited 2018 March 19]. Available from: http://nicedsu.org.uk/technical-support-documents/partitioned-survival-analysis-tsd/
   Google Scholar
• Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Stat Med. 2007;26:2389–2430.
   PubMed Web of Science ®Google Scholar
• R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. [cited 2019 Jan 5]. Available from: http://www.R-project.org/
   Google Scholar
• National Institute for Health and Care Excellence. DSU Technical Support Document 14: Survival analysis for economic evaluations alongside clinical trials – extrapolation with patient-level data; 2013. [cited 2018 March 9]. Available from: http://nicedsu.org.uk/wp-content/uploads/2016/03/NICE-DSU-TSD-Survival-analysis.updated-March-2013.v2.pdf
   Google Scholar
• Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. New York (NY): Oxford University Press; 2011.
   Google Scholar
• Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320–330.
   PubMed Web of Science ®Google Scholar
• Larkin J, Hodi FS, Wolchok JD. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:1270–1271.
   PubMed Web of Science ®Google Scholar
• Hodi FS, Chesney J, Pavlick AC, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2016;17:1558–1568.
   PubMed Web of Science ®Google Scholar
• Ascierto PA, McArthur GA, Dreno B, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016;17:1248–1260.
   PubMed Web of Science ®Google Scholar
• McArthur GA, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014;15:323–332.
   PubMed Web of Science ®Google Scholar
• Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386:444–451.
   PubMed Web of Science ®Google Scholar
• Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care. 2005;43:203–220.
   PubMed Web of Science ®Google Scholar
• Beusterien KSS, Kotapati S, et al. Societal preference values for advanced melanoma health states in the United Kingdom and Australia. Br J Cancer. 2009;101:385–387.
   Web of Science ®Google Scholar
• Middleton MR, Atkins MB, Amos K, et al. Societal preferences for adjuvant melanoma health states: UK and Australia. BMC Cancer. 2017;17:689.
   PubMed Web of Science ®Google Scholar
• Centers for Medicare & Medicaid Services. Physician Fee Schedule Search;2018. [cited 2019 Jan 5]. Available from: https://www.cms.gov/apps/physician-fee-schedule/search/search-criteria.aspx
   Google Scholar
• Bristol-Myers Squibb Company. Opdivo (nivolumab): prescribing information; 2018. [cited 2018 Dec 17]. Available from: https://packageinserts.bms.com/pi/pi_opdivo.pdf
   Google Scholar
• Bristol-Myers Squibb Company. Yervoy (ipilimumab): prescribing information; 2018. [cited 2018 Dec 17]. Available from: https://packageinserts.bms.com/pi/pi_yervoy.pdf
   Google Scholar
• Genentech. Cotellic (cobimetinib): prescribing information; 2015. [cited 2018 Dec 17]. Available from: https://www.gene.com/download/pdf/cotellic_prescribing.pdf
   Google Scholar
• Genentech. Zelboraf (vemurafenib): prescribing information; 2017. [cited 2018 Dec 17]. Available from: https://www.gene.com/download/pdf/zelboraf_prescribing.pdf
   Google Scholar
• Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib): prescribing information; 2018. [cited 2018 Dec 17]. Available from: https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/tafinlar.pdf
   Google Scholar
• Novartis Pharmaceuticals Corporation. Mekinist (trametinib): prescribing information; 2018. [cited 2018 Dec 17]. Available from: https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/mekinist.pdf
   Google Scholar
• National Institute for Health and Care Excellence. Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma [TA319]; 2014. [cited 2018 March 9]. Available from: https://www.nice.org.uk/guidance/ta319
   Google Scholar
• National Institute for Health and Care Excellence. Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab [TA357]; 2015. [cited 2018 March 9]. Available from: https://www.nice.org.uk/guidance/ta357
   Google Scholar
• Centers for Medicare & Medicaid Services. Acute inpatient prospective payment system. 2018. [Cited 2019 Jan 9]. Available from: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/FY2018-IPPS-Final-Rule-Home-Page.html
   Google Scholar
• Rashid N, Koh HA, Baca HC, et al. Economic burden related to chemotherapy-related adverse events in patients with metastatic breast cancer in an integrated health care system. BCTT. 2016;8:173–181.
   Google Scholar
• Wong W, Yim YM, Kim A, et al. Assessment of costs associated with adverse events in patients with cancer. PLoS One. 2018;13:e0196007.
   PubMed Web of Science ®Google Scholar
• Barzey V, Atkins MB, Garrison LP, et al. Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis. J Med Econ. 2013;16:202–212.
   PubMedGoogle Scholar
• Zhang Y, Le TK, Shaw JW, et al. Retrospective analysis of drug utilization, health care resource use, and costs associated with IFN therapy for adjuvant treatment of malignant melanoma. CEOR. 2015;7:397–407.
   Google Scholar
• Merck S, Dohme C. Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: a randomized, double-blind Phase 3 trial of the EORTC Melanoma Group: Clinical study report. 2018. Data cutoff date: 2 Oct 2017. Data on file.
   Google Scholar
• Seidler AM, Pennie ML, Veledar E, et al. Economic burden of melanoma in the elderly population: population-based analysis of the surveillance, epidemiology, and end results (SEER)-Medicare data. Arch Dermatol. 2010;146:249–256.
   PubMedGoogle Scholar
• Tarhini A, Corman SL, Rao S, et al. Healthcare resource utilization and associated costs in patients with advanced melanoma receiving first-line ipilimumab. JCT. 2015;06:833–840.
   Google Scholar
• Chastek B, Harley C, Kallich J, et al. Health care costs for patients with cancer at the end of life. J Oncol Pract. 2012;8:75s–80s.
   PubMedGoogle Scholar
• Institute for Clinical and Economic Review. Overview of the ICER value assessment framework and update for 2017–2019.
   Google Scholar
• Institute for Clinical and Economic Review. Overview of the ICER value assessment framework and update for 2017-2019. 2018. [cited 2019 Feb 1]. Available from: https://icer-review.org/wp-content/uploads/2017/06/ICER-value-assessment-framework-Updated-050818.pdf
   Google Scholar
• Suciu S, Eggermont AMM, Lorigan P, et al. Relapse-free survival as a surrogate for overall survival in the evaluation of stage II–III melanoma adjuvant therapy. J Natl Cancer Inst. 2018;110:87–96.
   Google Scholar